Zongertinib companion diagnostic - Boehringer Ingelheim/Guardant Health
Alternative Names: Zongertinib Guardant360® CDx; Zongertinib Guardant360® companion diagnosticLatest Information Update: 03 Feb 2025
Price :
$50 *
At a glance
- Originator Guardant Health
- Developer Boehringer Ingelheim; Guardant Health
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase Unknown Non-small cell lung cancer
Most Recent Events
- 18 Dec 2024 Gaurdant Health and Boehringer Ingelheim agree to co-develop Zongertinib Guardant360® companion diagnostic for Non-small cell lung cancer
- 18 Dec 2024 Investigation in Non-small cell lung cancer (Late-stage disease) in USA (unspecified route)
- 18 Dec 2024 Guardant Health and Boehringer Ingelheim intend to pursue regulatory approval of Guardant360 CDx companion diagnostic for zongertinib in Non-small cell lung cancer